Long-term clinical outcome of somatostatin analogues for treatment of progressive, metastatic, well-differentiated entero-pancreatic endocrine carcinoma

Panzuto, Francesco; Fonzo, M. Di; Iannicelli, Elsa; Sciuto, Rosa; Maini, C.L.; Capurso, Gabriele; Milione, Massimo; Cattaruzza, Maria Sofia; Falconi, Massimo; David, Vincenzo; Ziparo, Vincenzo; Pederzoli, Paolo; Bordi, Cesare; Fave, Gianfranco Delle

doi:10.1093/annonc/mdj113

Cited by 124 publications

(82 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Median survival or overall survival rates were reported in several studies, but the variability in time periods (1-, 2-, and 3-year survival rates were variously reported) made them difficult to compare [24,28,31,34,35,39]. The HR for overall survival in an interim analysis of PROMID was 0.81 (95% CI: 0.30 -2.18; p ϭ .77) [38], with further evaluation of overall survival to be made.…”

Section: Octreotidementioning

confidence: 99%

“…Analyses to identify prognostic factors for antitumor response identified tumor location [35,42,43], tumor progression (fast vs. slow) [24], and distant extrahepatic metastases [35] as significant factors. Trends were also found between functional and nonfunctional tumors, tumor locations, and hepatic tumor burdens [35,43,44].…”

Section: Lanreotidementioning

confidence: 99%

“…Trends were also found between functional and nonfunctional tumors, tumor locations, and hepatic tumor burdens [35,43,44].…”

Section: Lanreotidementioning

confidence: 99%

“…Survival benefits of patients responding to somatostatin analog treatment compared with nonresponders were reported in two studies that investigated both octreotide and lanreotide [24,35]. However, drug type was not investigated as a predictive factor.…”

Section: Lanreotidementioning

confidence: 99%

See 3 more Smart Citations

Antitumor Effects of Somatostatin Analogs in Neuroendocrine Tumors

2012

View full text Add to dashboard Cite

Background. For decades, somatostatin analogs (including octreotide and lanreotide) have been indicated for relief of the symptoms of flushing, diarrhea, and wheezing associated with secretory neuroendocrine tumors (NETs). Recently, it has been suggested that somatostatin analogs may provide direct and indirect antitumor effects in secretory and nonsecretory NETs in addition to symptom control in secretory NETs.Methods. A systematic review of MEDLINE was conducted to identify studies that investigated the antitumor effects of octreotide or lanreotide for patients with NETs. Additional studies not published in the peer-reviewed literature were identified by searching online abstracts.Results. In all, 17 octreotide trials and 11 lanreotide trials that included antitumor effects were identified. Partial response rates were between 0% and 31%, and stable disease

show abstract

Section: Octreotidementioning

confidence: 99%

Section: Lanreotidementioning

confidence: 99%

“…Trends were also found between functional and nonfunctional tumors, tumor locations, and hepatic tumor burdens [35,43,44].…”

Section: Lanreotidementioning

confidence: 99%

Section: Lanreotidementioning

confidence: 99%

See 2 more Smart Citations

Antitumor Effects of Somatostatin Analogs in Neuroendocrine Tumors

2012

View full text Add to dashboard Cite

show abstract

“…SSAs bind to somatostatin receptors to effectively decreasing hormone release and ameliorating clinical symptoms caused by hormonal derangement [5,91]. SSAs have also been shown to exert a cytostatic effect, which can result in disease stabilization and the lengthening of the median time to tumor progression [92].…”

Section: Somatostatin Analogues and Peptide Receptor Radiotherapymentioning

confidence: 99%

Pancreatic Neuroendocrine Tumors: an Update

2015

View full text Add to dashboard Cite

Pancreatic neuroendocrine tumors (pNETs) are rare and comprise only 1-2 % of all pancreatic neoplastic disease. Although the majority of these tumors are sporadic (90 %), pNETs can arise in the setting of several different hereditary genetic syndromes, most commonly multiple endocrine neoplasia type 1 (MEN1). The presentation of pNETs varies widely, with over 60 % having malignant distant disease at the time of initial diagnosis involving the liver or other distant sites. Functioning pNETs represent approximately 10 % of all pNETs, secrete a variety of peptide hormones, and are responsible for several clinical syndromes caused by profound hormonal derangement. Surgery remains the cornerstone of therapy and the only curative approach. It should be pursued for localized disease and for metastatic lesions amenable to resection. Multimodality therapies, including liver-directed therapies and medical therapy, are gaining increasing favor in the treatment of advanced pNETs. Their utility is multifold and spans from ameliorating symptoms of hormonal excess (functional pNETs) to controlling the local and systemic disease burden (non-functional pNETs). The recent introduction of target molecular therapy has promising results especially for the treatment of progressive well-differentiated G1/G2 tumor. In this review, we summarize the current knowledge and give an update on recent advancements made in the therapeutic strategies for pNETs.

show abstract

Zollinger–Ellison Syndrome

Jensen

2015

Yamada' S Textbook of Gastroenterology

View full text Add to dashboard Cite

Long-term clinical outcome of somatostatin analogues for treatment of progressive, metastatic, well-differentiated entero-pancreatic endocrine carcinoma

Cited by 124 publications

References 23 publications

Antitumor Effects of Somatostatin Analogs in Neuroendocrine Tumors

Antitumor Effects of Somatostatin Analogs in Neuroendocrine Tumors

Pancreatic Neuroendocrine Tumors: an Update

Zollinger–Ellison Syndrome

Contact Info

Product

Resources

About